The Phase I clinical trial of OMP - 54F28 (FZD8 - Fc) is an open - label dose escalation study in patients with advanced solid tumors for which there was no remaining
standard curative therapy.
Not exact matches
«Five - year survival data: Brentuximab vedotin may be
curative in some with Hodgkin lymphoma: Phase II trial suggests
therapy should be
standard of care for patients facing relapsed or treatment - resistant Hodgkin lymphoma.»
• Must not be a candidate for potentially
curative therapy or
standard - of - care approved
therapy • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.